Welcome to our dedicated page for Solventum news (Ticker: SOLV), a resource for investors and traders seeking the latest updates and insights on Solventum stock.
Solventum Corporation (NYSE: SOLV) generates a steady flow of news that reflects its role in the medical instruments and supplies sector and its focus on MedSurg, Dental Solutions and Health Information Systems. News about Solventum often highlights developments in advanced wound care, portfolio changes, capital allocation decisions and strategic initiatives intended to support long-term growth.
Recent announcements include agreements and completion of the acquisition of Acera Surgical, a bioscience company focused on fully engineered materials for regenerative wound care. These updates describe how Solventum is expanding its MedSurg portfolio into the synthetic tissue matrices technology space within acute care settings. Other news covers clinical and scientific developments, such as international consensus recommendations on the use of closed incision negative pressure therapy with reticulated open cell foam dressings, which relate directly to Solventum Prevena Therapy and its application across surgical specialties.
Investors and healthcare professionals following SOLV news will also see coverage of financial results, including quarterly earnings releases and guidance updates, as well as information about Solventum’s “Transform for the Future” initiative to reshape its cost structure and support innovation. Capital markets and balance sheet actions, such as cash tender offers for outstanding notes, the sale of the purification and filtration business to Thermo Fisher Scientific Inc., and the authorization of a share repurchase program, are reported through both press releases and SEC filings.
Additional news items may feature recognition of operational capabilities, such as the Diamond Level Resiliency Badge from the Healthcare Industry Resilience Collaborative for supply chain strength in the MedSurg segment, and participation in healthcare investor conferences. By reviewing the SOLV news feed on a regular basis, readers can track how Solventum’s strategic decisions, clinical evidence, portfolio moves and financial performance are communicated to the market over time.
Solventum (NYSE: SOLV) has completed the sale of its Purification & Filtration (P&F) business to Thermo Fisher Scientific (NYSE: TMO) for $4.0 billion in cash. The company will receive net proceeds of $3.4 billion, primarily allocated to debt reduction.
Following this strategic divestiture, Solventum has updated its FY2025 guidance, projecting organic sales growth of 2.0-3.0% and raising its adjusted EPS range to $5.88-$6.03. The company expects operating margins at the high end of 20-21% range and reduced net interest expense of $400 million, down from $450 million previously forecasted.
Solventum (NYSE: SOLV) announced its management's participation in two upcoming investor conferences. The company will attend the 2025 Wells Fargo Healthcare Conference in Boston on September 5, 2025, at 10:15 a.m. EDT, and the Morgan Stanley 23rd Annual Global Healthcare Conference in New York on September 9, 2025, at 10:45 a.m. EDT.
Both fireside chat sessions will be available through live and archived replays on the company's investor relations website at investors.solventum.com.
Solventum (NYSE:SOLV) has launched tender offers to purchase up to $1.75 billion of its outstanding notes. The offers are divided into two pools: Pool 1 with a maximum purchase amount of $1.25 billion covering four series of notes, and Pool 2 with a maximum of $500 million covering two series of notes.
Holders who tender their notes by the Early Tender Date of September 5, 2025, will receive the Total Consideration, which includes an Early Tender Payment of $30 per $1,000 principal amount. The tender offers will expire on September 22, 2025. The Early Settlement Date is expected around September 10, 2025, with the Final Settlement Date around September 25, 2025.
Solventum Corporation (NYSE: SOLV) has announced the pricing of a secondary offering of 8.8 million shares of common stock, which is expected to generate approximately $648 million in gross proceeds for 3M Company, the selling shareholder.
The offering, expected to close around August 15, 2025, is being managed by Goldman Sachs & Co. LLC and BofA Securities. Importantly, Solventum will not receive any proceeds from this transaction as all shares are being sold by 3M Company. The offering is being made through the company's shelf registration statement that became effective on August 13, 2025.
Solventum Corporation (NYSE: SOLV) has announced a secondary offering of 8,800,000 shares of its common stock, which will be sold entirely by 3M Company (the Selling Shareholder). The offering will be managed by Goldman Sachs & Co. LLC and BofA Securities, Inc. as underwriters.
The shares are being offered through Solventum's shelf registration statement on Form S-3, which became effective on August 13, 2025. Importantly, Solventum will not receive any proceeds from this offering as all shares are being sold by 3M Company. The offering will be conducted through a preliminary prospectus supplement and accompanying prospectus filed with the SEC.
Solventum (NYSE: SOLV) reported Q2 2025 financial results with sales increasing 3.9% to $2.2 billion and organic sales growth of 2.8%. The company achieved GAAP diluted EPS of $0.51 and adjusted diluted EPS of $1.69, marking five consecutive quarters of positive sales volume growth since implementing its transformation strategy.
Key financial metrics include operating cash flow of $169 million and free cash flow of $59 million. The company has increased its full-year 2025 guidance, projecting organic sales growth of 2.0% to 3.0% and adjusted EPS of $5.80 to $5.95. All segments showed positive organic growth, primarily driven by MedSurg and HIS segments.
Solventum (NYSE: SOLV) has scheduled its second quarter fiscal 2025 earnings release for Thursday, August 7, 2025, after U.S. market close. The company will host a webcast at 3:30 p.m. CDT / 4:30 p.m. EDT to discuss financial results and business updates.
Investors can access the webcast through the company's investor relations website at investors.solventum.com. The event will be available via phone with U.S. dial-in at +1 (800) 715-9871 and international dial-in at +1 (646) 307-1963, using Conference ID 6342275.
Following the event, a replay of the webcast, earnings release, presentation slides, and supplemental financial information will be accessible on Solventum's Investor Relations website.
Solventum (NYSE: SOLV) has announced its participation in the 2025 BofA Securities Health Care Conference. Company executives will engage in a fireside chat on Tuesday, May 13, 2025, at 2:20 p.m. PST in Las Vegas, NV. Investors and interested parties can access both live and archived replays of the presentation through the company's investor relations website at investors.solventum.com.